Aims: To evaluate the cost of illness from hypertension for the Italian Nat
ional Health System (NHS),
Methods and Results: A prospective analysis was carried out on clinical and
economic data recorded in the general practitioners' (GPs) database, Twent
y-one GPs working in the Ravenna area in Italy took part in the project on
a voluntary basis. The study included 1047 hypertensive patients enrolled b
etween 1 June and 31 December 1997 and continued for 365 days from the date
of enrolment, The following costs were calculated: antihypertensive drugs,
laboratory tests and instrumental procedures, GP visits for blood pressure
control, specialist visits, casualty visits, hospitalisation due to cardio
vascular problems. In the whole sample, the most relevant cost is due to an
tihypertensive drugs (42.7%), followed by hospital admission (28.4%), GP vi
sits (15.1%) and tests (10.6%), The total mean cost was significantly lower
in incident (no previous treatment) than in prevalent patients (already tr
eated) (457 512 vs 725 573 Italian Lira (ITL), P < 0.05) and in older rathe
r than in younger patients (1171 410 vs 796 452 (ITL) P < 0.05), (In the te
xt the equivalent is given in Euros, Pounds Sterling and US dollars).
Conclusion: Our study should be considered as preliminary, nevertheless it
could represent a step towards the evaluation of the true cost of hypertens
ion.